Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)
ID: 360195Type: Posted
Overview

Buyer

Centers for Disease Control and Prevention - ERA (HHS-CDC-HHSCDCERA)

Award Range

$0 - $500K

Eligible Applicants

Unrestricted

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360195
Timeline
    Description

    The Centers for Disease Control and Prevention (CDC) is inviting research proposals through a cooperative agreement to identify and evaluate potential risk factors for Amyotrophic Lateral Sclerosis (ALS). The opportunity encourages studies focusing on various aspects such as military service, contact sports, traumatic brain injury, neuroinflammation, and infectious agents, with four distinct funding options available to support both established and exploratory research. This initiative aims to enhance understanding of ALS risk factors, particularly in affected populations, and to analyze biological samples related to the Guamanian ALS cluster. Interested applicants can reach out to Dr. Candis Hunter at ncipc_erpo@cdc.gov or by phone at 770-488-1347. The total estimated funding for this program is $7.5 million, with individual awards ranging from $0 to $500,000, and proposals are due by December 1, 2025, with awards expected to be announced by August 28, 2026.

    Point(s) of Contact
    Dr. Candis Hunter
    (770) 488-1347
    ncipc_erpo@cdc.gov
    Files
    No associated files provided.
    Similar Opportunities
    Studies Addressing Rare Neurodegenerative Diseases including ALS
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for studies addressing rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). This grant aims to support research that advances the development of medical products intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in both adults and children. The initiative is crucial for addressing significant knowledge gaps in the field and is expected to have a substantial impact on the development of interventions for these conditions. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610 for further information. The FDA anticipates awarding approximately 10 grants in fiscal year 2025, with no cost-sharing or matching requirements.
    Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for research on amyotrophic lateral sclerosis (ALS) through the "Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)" grant. This initiative aims to support clinical trial sites that participate in phase 2/3 or phase 3 efficacy trials for investigational drugs or biological products targeting ALS, specifically for patients who are not eligible for ongoing clinical trials. Given the urgent need for effective treatments for ALS, which affects over 32,000 individuals in the U.S. and has limited existing therapeutic options, this funding will facilitate research that utilizes data from expanded access protocols to improve patient outcomes. The estimated total program funding is $40 million, with four awards expected, and interested applicants can reach out to Dr. Amy Tsou at amy.tsou@nih.gov or (240) 987-2815 for further information. The application process is anticipated to open with a synopsis posted on October 29, 2025, and the estimated award date is September 1, 2026.
    Continuation and Expansion of the National Mesothelioma Virtual Bank for Translational Research (U24)
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is offering a funding opportunity for the continuation and expansion of the National Mesothelioma Virtual Bank for Translational Research (U24). This cooperative agreement aims to enhance the collection of biospecimens and related data to support biomedical research on malignant mesothelioma, requiring applicants to have an established registry and tissue bank capable of functioning as a national resource. The initiative is crucial for advancing research into early disease markers, treatment modalities, and improving health outcomes for mesothelioma patients. The total estimated funding for this program is $5.5 million, with a ceiling and floor award amount of $1.1 million, and applications must be submitted electronically by March 23, 2026, with an anticipated award date of August 1, 2026. For further inquiries, interested parties can contact Bridgette Garrett at bgarrett@cdc.gov or by phone at 770-488-5715.
    Promoting Resources and Opportunities for People with Autism and Fragile X and their Families Across the Lifespan
    Centers for Disease Control - NCBDDD
    The Centers for Disease Control and Prevention (CDC) is offering a cooperative agreement grant titled "Promoting Resources and Opportunities for People with Autism and Fragile X and their Families Across the Lifespan." This initiative aims to gather unique data to enhance understanding of the resources and opportunities necessary to improve outcomes for individuals with autism and Fragile X Syndrome (FXS) throughout their lives. The program consists of three components: data collection on autistic teens and young adults, data collection on individuals with FXS, and dissemination of public health products to support these populations. The total estimated funding for this program is $18 million, with 11 awards expected to be made. Interested applicants can reach out to Seema Gupta at (770) 488-6527 or via email at cvk9@cdc.gov for further information. Applications must be submitted electronically by January 30, 2026, with the project anticipated to start on July 1, 2026.
    Preparedness for and Prevention of Severe Disease and Sequelae of Respiratory Viruses and Other Respiratory Pathogens
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is offering a funding opportunity titled "Preparedness for and Prevention of Severe Disease and Sequelae of Respiratory Viruses and Other Respiratory Pathogens" through a cooperative agreement. This initiative aims to support research focused on preventing and mitigating severe respiratory illnesses and their complications by investigating the epidemiology, prevention, treatment, and outcomes associated with respiratory viruses and other pathogens. The program is crucial for enhancing public health infrastructure and clinical outcomes related to respiratory diseases, particularly for high-risk populations such as pregnant women, infants, and older adults. The total estimated funding for this program is $50 million, with individual awards ranging from $1.5 million to $2 million, and applications are due by March 1, 2026. Interested applicants can reach out to Amy Yang at AYang@cdc.gov or call 404-718-8836 for further information.
    Eliminating Parasitic and Neglected Tropical Disease Threats to the United States - Program Support and Research to Reduce Threats to Americans at Home and Abroad
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is offering a funding opportunity titled "Eliminating Parasitic and Neglected Tropical Disease Threats to the United States," aimed at expanding its network of collaborating institutes for research and program support. The initiative seeks to achieve, accelerate, or maintain outcomes for the elimination or control of non-malaria parasitic threats and neglected tropical diseases that impact the health of Americans domestically and internationally. This cooperative agreement has an estimated total program funding of $10 million, with individual awards ranging from $500,000 to $666,667, and is expected to result in three awards. Interested applicants can reach out to Amy Yang at AYang@cdc.gov or by phone at 404-718-8836, with applications due by March 1, 2026, and awards anticipated by September 15, 2026.
    Comprehensive Suicide Prevention Program for States
    Centers for Disease Control - NCIPC
    The Centers for Disease Control and Prevention (CDC) is offering a funding opportunity titled "Comprehensive Suicide Prevention Program for States," aimed at implementing and evaluating a comprehensive approach to suicide prevention, particularly for disproportionately affected populations such as veterans, rural communities, and LGBTQ individuals. Eligible applicants must submit proposals with a funding request between $650,000 and $1,200,000, including various letters of commitment and support, as well as a preliminary organizational chart detailing required staff roles. The total estimated program funding is approximately $49.7 million, with an expected 42 awards to be made, and applications must be submitted electronically by 11:59 PM ET on March 3, 2026, with the anticipated award date set for June 19, 2026. For further inquiries, applicants can contact the Comprehensive Suicide Prevention mailbox at csp@cdc.gov.
    Collaborative Surveys to Provide Inputs into Vaccine-Related Economic Evaluations
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is offering a funding opportunity titled "Collaborative Surveys to Provide Inputs into Vaccine-Related Economic Evaluations" through a cooperative agreement. This initiative aims to support research that gathers timely economic data on immunization from nationally representative samples of the public, including patients and caregivers, to inform economic evaluations of new vaccines. The program is critical for understanding productivity losses related to immunization, particularly for vulnerable populations such as pregnant women and parents of young children. The estimated total funding for this program is $1.2 million, with individual awards ranging from $300,000 to $400,000. Interested applicants can reach out to Amy Yang at AYang@cdc.gov or by phone at 404-718-8836, with applications due by March 31, 2026, and project start anticipated on September 1, 2026.
    Building National Partnerships for the Prevention of Emerging and Reemerging Infectious Diseases
    Centers for Disease Control - NCEZID
    The Centers for Disease Control and Prevention (CDC) is offering a cooperative agreement titled "Building National Partnerships for the Prevention of Emerging and Reemerging Infectious Diseases." This initiative aims to enhance the nation's capacity to prevent, detect, and respond to infectious disease threats by supporting healthcare professionals, systems, and organizations involved in public health and patient care. The program emphasizes strengthening critical infrastructure, workforce training, and emergency response capabilities, particularly focusing on antimicrobial resistance and infection control. With an estimated total funding of $150 million, the CDC anticipates awarding approximately 15 grants, with individual awards ranging from $1 million to $30 million. Interested applicants can contact Trisia Shannon at 404-639-0063 or via email at xki5@cdc.gov, with applications due by April 18, 2026, and project start dates expected by September 30, 2026.
    Exploratory/Developmental Grants Related to the World Trade Center Health Program (R21)
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is offering exploratory and developmental grants related to the World Trade Center Health Program (R21) to support research addressing diagnostic and treatment uncertainties for individuals affected by the 9/11 attacks. This funding opportunity aims to encourage innovative research projects that explore new areas of investigation, potentially leading to significant advancements in treatment effectiveness and diagnostic practices for those receiving monitoring and treatment under the James Zadroga 9/11 Health and Compensation Act. With an estimated total program funding of $30 million and an expected 60 awards, applicants can request funding ranging from $0 to $365,000. Interested parties should note that applications are due by 5:00 PM local time on February 12, 2026, and can direct inquiries to Dr. Eduardo O'Neill at 404-718-8844 or via email at fzt4@cdc.gov.